Investigating how to inhibit a key protein in mycobacteria to combat infections
Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria
This study is looking for new ways to fight tuberculosis by testing different compounds that can block a protein called MmpL3, which is crucial for the survival of the bacteria, with the hope of creating better treatments for patients, especially those with tough-to-treat infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10887650 on NIH RePORTER |
What this research studies
This research focuses on MmpL3, a protein essential for the survival of mycobacteria, including the bacteria that cause tuberculosis. By identifying and testing new compounds that inhibit MmpL3, the research aims to develop effective treatments against mycobacterial infections. The approach includes high-throughput screening of potential inhibitors and studying their effects on bacterial growth in laboratory settings. Patients may benefit from new therapies that target resistant strains of mycobacteria, improving treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from tuberculosis or other mycobacterial infections, particularly those with drug-resistant strains.
Not a fit: Patients with non-mycobacterial infections or those who do not have a history of tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively treat drug-resistant mycobacterial infections.
How similar studies have performed: Previous research has shown promise in targeting MmpL3, indicating that this approach could lead to significant advancements in treating mycobacterial infections.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Abramovitch, Robert B — Michigan State University
- Study coordinator: Abramovitch, Robert B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.